Who, when and how? A look at the UK's vaccination rollout

British regulators have become the first to approve the COVID-19 vaccine developed by American drugmaker Pfizer and Germany's BioNTech for experimental use.

Because trials of the vaccine have shown that it has 95 per cent efficacy, there is acute interest in how the U.K. plans to implement its biggest immunisation programme in decades. Here's a look at what is known about Britain's vaccination plan: 

HOW MUCH OF THE VACCINE DOES THE U.K. HAVE? 

Not enough. The U.K. has put in orders for 40 million doses, which can inoculate 20 million people since each person gets two doses of the vaccine 21 days apart. Because the UK will only immunise people over age 16, it means that it will have to find other vaccines for all 53 million or so people who are eligible for shots.

The plan is to rollout the Pfizer/BioNTech vaccine in the next few days after the first batch arrives from Belgium. British Health Secretary Matt Hancock said 800,000 doses will arrive next week, with millions coming in the following weeks.

It won't be straightforward. Because the vaccine must be stored and transported at about minus 70 degrees Celsius (minus 94 degrees Fahrenheit), there are clear logistical issues.

Luckily, the vaccine is stable at normal fridge temperatures, between 2 and 8 degrees Celsius (35.6 to 46.4 F), for a few days, meaning that it can be stored locally ahead of being administered. The U.K. is planning to use the National Health Service to roll the vaccine out, including local general practitioners and specially built vaccination centers.

HOW LONG WILL THE VACCINATION EFFORT TAKE? 

A few months at least.

Because the U.K. does not have enough of Pfizer/BioNTech vaccine, it will need other vaccines. Two others are currently being assessed. The one from American biotechnology company Moderna had similar efficacy rates as the one from Pfizer/BioNTech.

Another vaccine from the University of Oxford and British pharmaceutical company AstraZeneca had a lower efficacy rate but is far cheaper than the other two. The U.K. has bought 100 million doses of the AstraZeneca vaccine, which if approved is widely expected to be rolled out to those people not in the first phase of Britain's immunisation programme.

No. Taking the vaccine will be voluntary, but the government and public health bodies are strongly urging everyone to take it. There will be no specific precautions required for anyone who has already had COVID 19 and there will no testing for the virus before anyone receives the vaccine.

The most vulnerable. The independent Joint Committee on Vaccination and Immunisation, which advises the British government on the rollout, said those most at risk of dying from COVID-19 should be top of the priority list. So elderly people in nursing homes and their caregivers will be the first priority, followed by people aged over 80 and front-line health workers.

All residents 75 and older should be vaccinated next, according to the JCVI, followed by those 70 and over and people deemed to be clinically “extremely vulnerable.” During the first phase of the immunisation program, Britain has created nine separate groups down to those aged 50 and above. Overall, it hopes that between 90-99% of people most at risk of dying from COVID 19 will have been immunized during the first phase of the vaccinations.

No. The Joint Committee on Vaccination and Immunization acknowledged that the scale of the vaccination program is unprecedented and that operational flexibilities will be required. There are clear questions to be answered as to how the Pfizer vaccine will be transported to nursing homes, given the need for it to be stored and transported at super-low temperatures.

Within a month. Data from the vaccine trials, which involved more than 40,000 people around the world, shows a similar immune response, irrespective of age, race or country the volunteers lived in. Partial immunity does occur after the first dose, but British regulators expect people to become immune about seven days after the second dose. It is not yet exactly clear how long that immunity lasts.

There are a number of answers that will only emerge through the test of time, such as its impact on transmission rates. It's also not clear how long immunity will last and whether people will need an annual dose of the vaccine, as with the flu vaccine.

It's also unclear how the coronavirus will develop, whether it morphs into different strains. The U.K. will set up a monitoring program, whereby people will be asked to help build up knowledge. First up will be side-effects. They are expected to be modest, lasting a day or so and equivalent to those after other vaccines.

Britain's Medicines and Healthcare Products Regulatory Agency, which authorized the Pfizer-BioNTech vaccine, insists no corners were cut in the process and that the experience of the vaccination rollout will show that the vaccine is safe and effective. The government has also indicated it will seek to stem anti-vax misinformation and is thought to be actively recruiting well-respected people to front a national immunization ad campaign.